Another study revealed that MIF expression was negatively correlated with the efficiency of anti-PD-l combined with chemotherapy as a neoadjuvant therapy, suggesting that it could not only be a biomarker for a bad prognosis in ESCC but also a predictive biomarker for the effectiveness of the treatment for ESCC (142). This evidence concerns the gene MIF and esophageal squamous cell carcinoma.